Enzon Pharmaceuticals Stock Earnings Per Share
| ENZNDelisted Stock | USD 0.20 0.01 5.26% |
Enzon Pharmaceuticals fundamentals help investors to digest information that contributes to Enzon Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Enzon OTC Stock. The fundamental analysis module provides a way to measure Enzon Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enzon Pharmaceuticals otc stock.
Enzon |
Enzon Pharmaceuticals OTC Stock Earnings Per Share Analysis
Enzon Pharmaceuticals' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Enzon Pharmaceuticals Earnings Per Share | (0.04) X |
Most of Enzon Pharmaceuticals' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enzon Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Enzon Pharmaceuticals has an Earnings Per Share of -0.038 times. This is 100.45% lower than that of the Biotechnology sector and 99.21% lower than that of the Health Care industry. The earnings per share for all United States stocks is 101.22% higher than that of the company.
Enzon Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enzon Pharmaceuticals' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Enzon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Enzon Pharmaceuticals by comparing valuation metrics of similar companies.Enzon Pharmaceuticals is currently under evaluation in earnings per share category among its peers.
Enzon Fundamentals
| Return On Equity | -0.016 | ||||
| Return On Asset | -0.0138 | ||||
| Operating Margin | (36.28) % | ||||
| Current Valuation | 17.63 M | ||||
| Shares Outstanding | 74.21 M | ||||
| Shares Owned By Insiders | 10.70 % | ||||
| Shares Owned By Institutions | 48.58 % | ||||
| Number Of Shares Shorted | 259.38 K | ||||
| Price To Earning | 1.52 X | ||||
| Price To Book | 7.41 X | ||||
| Price To Sales | 669.36 X | ||||
| Revenue | 701 K | ||||
| Gross Profit | 701 K | ||||
| EBITDA | (469 K) | ||||
| Net Income | (469 K) | ||||
| Cash And Equivalents | 46.79 M | ||||
| Cash Per Share | 0.63 X | ||||
| Debt To Equity | 1.46 % | ||||
| Current Ratio | 125.26 X | ||||
| Book Value Per Share | 0.04 X | ||||
| Cash Flow From Operations | (501 K) | ||||
| Short Ratio | 1.71 X | ||||
| Earnings Per Share | (0.04) X | ||||
| Target Price | 14.0 | ||||
| Beta | 0.17 | ||||
| Market Capitalization | 19.72 M | ||||
| Total Asset | 47.75 M | ||||
| Retained Earnings | (75.61 M) | ||||
| Working Capital | 6.98 M | ||||
| Current Asset | 11.78 M | ||||
| Current Liabilities | 4.8 M | ||||
| Z Score | -1.4 | ||||
| Annual Yield | 0.65 % | ||||
| Net Asset | 47.75 M |
About Enzon Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enzon Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enzon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enzon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Enzon Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enzon Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enzon Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Enzon OTC Stock
The ability to find closely correlated positions to Enzon Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enzon Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enzon Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enzon Pharmaceuticals to buy it.
The correlation of Enzon Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enzon Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enzon Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enzon Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in nation. Note that the Enzon Pharmaceuticals information on this page should be used as a complementary analysis to other Enzon Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Enzon OTC Stock
If you are still planning to invest in Enzon Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Enzon Pharmaceuticals' history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |